• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

    10.51 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,590
    Open 10.51
    Bid (Size) 10.31 (600)
    Ask (Size) 10.45 (3,700)
    Prev. Close 10.51
    Today's Range 10.51 - 10.51
    52wk Range 6.280 - 14.80
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire

    Performance

    YTD
    +37.9%
    +37.9%
    1 Month
    +2.9%
    +2.9%
    3 Month
    +3.1%
    +3.1%
    6 Month
    +37.9%
    +37.9%
    1 Year
    -27.9%
    -27.9%

    More News

    Read More
    News headline image
    Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    FDA Alignment to Advance ProstACT Global Phase 3 Trial
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix and United Imaging Announce Strategic Theranostics Collaboration
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    TLX101-Px (Pixlumi®) MAA Accepted in Europe
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)
    Via Finterra
    Topics Economy Initial Public Offering
    News headline image
    Telix and Regeneron Announce Strategic Radiopharma Collaboration
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Regeneron and Telix Announce Strategic Radiopharma Collaboration
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    FDA Accepts NDA for TLX101-Px (Pixclara®)
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Strengthens Board with Additional Director Appointments
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Appoints David Gill as Non-Executive Director
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire

    Frequently Asked Questions

    Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?
    Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.
    What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?
    Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?
    The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market
    What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?
    The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 10.51
    When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?
    The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 07/23/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.